Citius Oncology, Inc. Other Research and Development Expense
Citius Oncology, Inc. (CTOR) reported Other Research and Development Expense of $256.23 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-08-14
- Citius Oncology, Inc. other research and development expense for the quarter ending 2026-06-30 was $256.23K, a 46.62% decline year-over-year.
- Citius Oncology, Inc. other research and development expense for the quarter ending 2026-03-31 was $469.00K, a 2.29% decline year-over-year.
- Citius Oncology, Inc. other research and development expense for the quarter ending 2025-12-31 was $480.00K, a 0.00% change year-over-year.
- Citius Oncology, Inc. other research and development expense for the quarter ending 2025-09-30 was $480.00K, a 0.35% decline year-over-year.
- Citius Oncology, Inc. other research and development expense for fiscal 2025 was $1.92M, a 2.22% decline from fiscal 2024.
- Citius Oncology, Inc. other research and development expense for fiscal 2024 was $1.96M, a 31.22% increase from fiscal 2023.
- Citius Oncology, Inc. other research and development expense for fiscal 2023 was $1.50M.
| Period end | Other Research and Development Expense 3 month | Other Research and Development Expense 6 month | Other Research and Development Expense 9 month | Other Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $256.23K 10-Q · filed 2026-08-14 | $725.23K derived: sum of 2 quarters · filed 2026-08-14 | $1.21M 10-Q · filed 2026-08-14 | $1.69M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $469.00K 10-Q · filed 2026-05-15 | $949.00K 10-Q · filed 2026-05-15 | $1.43M derived: sum of 3 quarters · filed 2026-05-15 | $1.91M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $480.00K 10-Q · filed 2026-02-13 | $960.00K derived: sum of 2 quarters · filed 2026-02-13 | $1.44M derived: sum of 3 quarters · filed 2026-08-14 | $1.92M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $960.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.44M derived: sum of 3 quarters · filed 2026-08-14 | $1.92M 10-K · filed 2025-12-23 |
| 2025-06-30 | $480.00K 10-Q · filed 2026-08-14 | $960.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.44M 10-Q · filed 2026-08-14 | $1.92M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $480.00K 10-Q · filed 2026-05-15 | $960.00K 10-Q · filed 2026-05-15 | $1.44M derived: sum of 3 quarters · filed 2026-05-15 | $1.96M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $480.00K 10-Q · filed 2026-02-13 | $961.67K derived: sum of 2 quarters · filed 2026-02-13 | $1.48M derived: sum of 3 quarters · filed 2026-02-13 | $1.96M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $481.67K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $997.50K derived: sum of 2 quarters · filed 2025-12-23 | $1.48M derived: sum of 3 quarters · filed 2025-12-23 | $1.96M 10-K · filed 2025-12-23 |
| 2024-06-30 | $515.84K 10-Q · filed 2025-08-12 | $998.90K derived: sum of 2 quarters · filed 2025-08-12 | $1.48M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $483.06K 10-Q · filed 2025-05-14 | $966.13K 10-Q · filed 2025-05-14 | ||
| 2023-12-31 | $483.06K 10-Q · filed 2025-02-14 | |||
| 2023-09-30 | $1.50M 10-K · filed 2024-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |